News Briefs: Aetna Alleges ‘Far-Reaching Conspiracy’ in Price-Fixing Lawsuit
-
Jan 09, 2025
CVS Health Corp.-owned Aetna filed a lawsuit on Dec. 30 against several pharmaceutical manufacturers, alleging they engaged in price-fixing. The insurer is seeking damages it incurred “from egregious overcharges it paid for certain widely used generic drugs, arising from a far-reaching conspiracy among Defendants and others to blatantly fix the price of such drugs,” according to the lawsuit, which was filed in Superior Court in Hartford, Connecticut. Aetna wrote that the “conspiracy…infected the entire generic marketplace” and “was designed to evade detection.” The alleged scheme, according to the lawsuit, involved the companies working together to dissuade competition and assign certain manufacturers to specific markets.
Amgen Inc. has chosen Optum’s new biosimilars-focused private-label subsidiary, Nuvaila, to be the sole distributor of Wezlana (ustekinumab-auub), the first Stelara biosimilar, AIS Health’s Radar on Specialty Pharmacy reports. The new interchangeable biosimilar launched on Jan. 1. It is approved for all of Stelara’s indications and is available in subcutaneous and intravenous formulations. At least seven more Stelara biosimilars are expected to launch after Wezlana. Stelara is approved for treating patient who are at least 6 years old with moderate-to-severe plaque psoriasis and who are candidates for phototherapy or systemic therapy; patients who are at least 6 years old with active psoriatic arthritis; adults with moderately to severely active Crohn’s disease; and adults with moderately to severely active ulcerative colitis.
Read more
© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.